GC
Tigermed Consulting kicks off Hong Kong secondary listing
Shenzhen-listed Hangzhou Tigermed Consulting has caught the attention of international and local investors for its secondary listing on the Hong Kong exchange, set to be worth at least $1bn.
Tigermed is a biopharmaceutical research and development service provider. According to a report by Frost & Sullivan cited in its listing documents, it was the leading contract research organisation (CRO) in China, based on revenue and clinical trials in 2019.
It began pre-marketing to investors on Monday through ...Already a subscriber? Login
